Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism

Turgeon, Jacques; Pharand, Chantal; Michaud, Véronique
June 2006
CMAJ: Canadian Medical Association Journal;6/6/2006, Vol. 174 Issue 12, p1729
Academic Journal
Comments on a study on the efficacy of the drug clopidogrel in the presence of cytochrome p450 polymorphism. Risk of atherothrombotic events in people taking clopidogrel; Frequency of atherothrombotic events in a follow-up period among patients who underwent coronary angioplasty with bare-metal stent implantation and antiplatelet therapy with clopidogrel; Role of platelets in the pathogenesis of atherothrombotic events.


Related Articles

  • Clopidogrel Bisulfate: A Review of its Use in the Management of Acute Coronary Syndrome. Rossini, Roberta; Musumeci, Giuseppe; Nijaradze, Tamar; Gavazzi, Antonello // Clinical Medicine: Therapeutics;2009, Issue 1, p899 

    Antiplatelet therapy is the cornerstone in the modern therapy of patients with acute coronary syndromes (ACS), because of the unique role of platelets in coronary thrombosis. Clopidogrel in combination with aspirin is the current "gold standard" for reducing cardiovascular events in such...

  • tirofiban.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1153 

    This article presents a nurse's guide to the antiplatelet agent tirofiban. Tirofiban is indicated for the treatment of acute coronary syndrome, including patients who will be managed medically and those who will undergo percutaneous transluminal angioplasty or atherectomy. It acts by decreasing...

  • Percutaneous Coronary Intervention.  // Current Medical Literature: Interventional Cardiology Monitor;2006, Vol. 13 Issue 3, p78 

    The article assesses several studies regarding percutaneous coronary intervention. A study focused on the clinical challenges in major non-cardiac surgery. Another study concluded that abciximab lessen the complications of acute coronary syndromes in patients. One study dealt with dual...

  • Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. A. Palumbo; F. Gay; S. Bringhen; A. Falcone; N. Pescosta; V. Callea; T. Caravita; F. Morabito; V. Magarotto; M. Ruggeri; I. Avonto; P. Musto; N. Cascavilla; B. Bruno; M. Boccadoro // Annals of Oncology;Jun2008, Vol. 19 Issue 6, p1160 

    Background: Bortezomib has shown significant activity in myeloma. In this multicenter trial, we assessed for the first time the combination of bortezomib, doxorubicin and low-dose dexamethasone (PAd) in the treatment of relapsed/refractory myeloma. Patients and methods: Sixty-four patients were...

  • AZD6140 demonstrated inhibition of platelet aggregation. Haigh, Christen; Thadani, Udho // Cardiology Today;Jan2008, Vol. 11 Issue 1, p25 

    The article discusses research being done on the effectiveness of AZD6140 in suppressing platelet aggregation in clopidogrel-pretreated patients and patients with acute coronary syndromes. It references a study by Robert F. Storey and colleagues, published in the 2007 issue of the "Journal of...

  • Effects of Nisoldipine on Cytosolic Calcium, Platelet Aggregation, and Coagulation/Fibrinolysis in Patients with Coronary Artery Disease. Fujinishi, Akiko; Takahara, Kazuo; Ohba, Chizuko; Nakashima, Yasuhide; Kuroiwa, Akio // Angiology;Jun1997, Vol. 48 Issue 6, p515 

    The effect of nisoldipine, a dihydropyridine Ca2+ antagonist, on the platelet cytosolic Ca2+ concentration ([Ca2+]i), platelet aggregation, and various coagulation and fibrinolysis parameters was assessed in normotensive patients with coronary artery disease (CAD). Eleven patients with...

  • Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond. Walsh, S. J.; Spence, M. S.; Crossman, D.; Adgey, A. A. J. // Heart;Sep2005, Vol. 91 Issue 9, p1135 

    This article evaluates the effectiveness of the use of clopidogrel in the treatment of acute coronary syndromes. Clopidogrel is a thienopyridine derivative that inhibits the platelet ADP receptor. Metabolism of clopidogrel by the hepatic cytochrome P450 system produces an active metabolite and...

  • Therapeutic Concentrations of Heparin Augment Platelet Activation at the Time of Coronary Angiography. Naqvi, Tasneem Z.; Shah, Prediman K.; Ivey, Pamela A.; Molloy, Mia D.; Linn, Patricia; Linker-Israeli, Mariana; Cercek, Bojan; Kaul, Sanjay // Journal of Cardiovascular Pharmacology & Therapeutics;Jun1998, Vol. 3 Issue 2, p91 

    The article presents a study to determine the effects of unfractionated herapin on platelet function in patients with stable coronary artery disease (CAD). It was noted that intravenous administration of herapin augmented platelet activation in patients at clinically relevant anticoagulant...

  • AZD6140 demonstrated inhibition of platelet aggregation. Haigh, Christen; Thadani, Udho // Endocrine Today;1/10/2008, Vol. 6 Issue 1, p18 

    The article discusses a research on the efficacy of clopidogrel against AZD6140 in suppressing platelet aggregation in clopidogrel-pretreated patients or inhibiting platelet aggregation in patients with acute coronary syndromes. It references a study by Robert F. Storey et al, published in the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics